PPI Use Is Associated With Fatty Liver Disease and Liver Dysfunction
Yes, long-term PPI use is linked to an increased risk of fatty liver disease, elevated ALT, and various forms of liver dysfunction, though the 2022 AGA guidelines emphasize that these potential adverse events should not independently drive decisions to discontinue PPIs when a clear indication exists.
Key Evidence on Hepatic Risks
The most robust recent evidence demonstrates a clear association between PPI use and fatty liver disease:
Long-term use (>5 years) significantly increases NAFLD risk with an odds ratio of 2.016 (95% CI: 1.366-2.975), while shorter duration use (<5 years) shows no significant association 1. This 2024 U.S. population study found PPIs particularly associated with severe hepatic steatosis (OR: 1.451) rather than mild-to-moderate disease.
A 2021 Korean nationwide cohort study found PPI users had a 50% increased risk of fatty liver disease (adjusted HR: 1.50,95% CI: 1.44-1.57) with a dose-response relationship up to 180 days of cumulative use 2.
Spectrum of Liver-Related Adverse Effects
Beyond fatty liver, PPIs are associated with multiple hepatic complications:
Cholestatic Injury Pattern
The predominant pattern of liver injury from PPIs is cholestatic rather than hepatocellular 3. FDA adverse event data shows the highest risk signals for:
- Cholestatic hepatitis (esomeprazole ROR: 21.556; pantoprazole ROR: 22.611)
- Fulminant hepatitis
- Subacute hepatic failure
In Cirrhotic Patients
PPIs pose particular risks in patients with existing liver disease 4, 5:
- Increased hepatic decompensation events (OR: 2.9)
- Higher infection risk (OR: 2.4)
- Elevated risk of hepatic encephalopathy (OR: 1.76), though this finding has publication bias concerns 6
- Increased mortality in cirrhosis
Clinical Decision Framework
When PPI Benefits Outweigh Hepatic Risks
The 2022 AGA guidelines explicitly state that the presence of a PPI-associated adverse event or risk factors for such events should NOT be an independent indication for PPI withdrawal 7. Continue PPIs when there are definitive indications:
- Complicated GERD (severe erosive esophagitis, esophageal ulcer, peptic stricture)
- Barrett's esophagus
- High gastrointestinal bleeding risk
- Active peptic ulcer disease
When to Consider De-Prescribing
All patients without a definitive indication for chronic PPI use should be considered for de-prescribing 7. This is particularly important given:
- 77% of cirrhotic patients receive PPIs, but only 31% have clear indications 5
- The dose-response relationship with fatty liver risk
- The association with severe (not mild) hepatic steatosis
Practical Monitoring Approach
For patients requiring long-term PPI therapy:
- Document and regularly review the ongoing indication - this is the primary care provider's responsibility 7
- Monitor for hepatic steatosis development, particularly after 5 years of use
- Consider step-down from twice-daily to once-daily dosing when appropriate 7
- Be aware that ALT elevation may signal developing MAFLD, though ALT lacks specificity 8
Critical Caveats
The decision to continue or discontinue PPIs should be based solely on the presence or absence of a valid indication, not fear of adverse events 7. The observational nature of most hepatic risk data means causality is not definitively established, while randomized trials have not shown increased adverse events with PPIs 7. However, the consistency of findings across multiple large cohort studies warrants clinical awareness and judicious prescribing practices.